We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares

Delisted

FUSN was delisted on the 3rd of June, 2024.

77 hedge funds and large institutions have $586M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 4

351% more capital invested

Capital invested by funds: $130M → $586M (+$456M)

244% more call options, than puts

Call options by funds: $592K | Put options by funds: $172K

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

88% more funds holding

Funds holding: 4177 (+36)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
77
Holders Change
+36
Holders Change %
+87.8%
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
40
Increased
17
Reduced
8
Closed
4
Calls
$592K
Puts
$172K
Net Calls
+$420K
Net Calls Change
+$420K
Name Holding Trade Value Shares
Change
Change in
Stake
TWC
76
TD Waterhouse Canada
Ontario, Canada
$5.92K
Osaic Holdings
77
Osaic Holdings
Arizona
$826 +$418 +86 New
GTC
78
Ghost Tree Capital
New York
-$633K -243,287 Closed
LSA
79
Leonteq Securities AG
Switzerland
-$91K -35,000 Closed
DWA
80
Dorsey Wright & Associates
California
-$2.28K -878 Closed
National Bank of Canada
81
National Bank of Canada
Quebec, Canada
-$1.19K -500 Closed

FUSN Hedge Fund Activity: Q4 2023 in Review

77 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q4 2023, worth a combined $586M — up 351% from $130M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new FUSN positions and 4 closed out — a net gain of 36 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Deerfield Management, adding an estimated $17.4M. The largest seller was Artal Group, cutting an estimated $3.5M.

  • 77 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q4 2023, up from 41 in Q3 2023.
  • Funds reported $586M of Fusion Pharmaceuticals Inc. Common Shares stock for Q4 2023, up 351% quarter-over-quarter.
  • 40 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q4 2023 and 4 closed out, a net change of +36 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q4 2023 was Deerfield Management, an estimated $17.4M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q4 2023 was Artal Group, an estimated $3.5M sold.

Based on aggregated 13F filings for Q4 2023.